Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Risk of venous and arterial thromboembolic events following CAR-T therapy in relapsed or refractory non-Hodgkin lymphoma: A propensity-matched multicenter analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

FNFaris NaffaRYRahaf YaghiKAKirti Arora

Discussion

Loading...

Member takes

Overview

Analysis demonstrates increased rates of venous thromboembolism and acute limb ischemia in NHL patients after CAR-T therapy, suggesting a need for preventive strategies.

Key Points

  • CAR-T therapy resulted in a significant increase in venous thromboembolic events compared to non-CAR-T controls.
  • The 90-day risk of venous thromboembolism was 15.5% in CAR-T patients versus 10.5% in matched controls, with risks calculated using a 1:1 propensity score approach.
  • Assessment of thromboembolic events included evaluations of myocardial infarction, ischemic stroke, and acute limb ischemia over a 90-day period.
  • Findings suggest close monitoring and potential prophylactic medication may be necessary to mitigate thromboembolic risks post-CAR-T therapy.

Cite This Study

Naffa et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df65https://doi.org/10.1182/blood-2025-3729
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Thromboembolic and cardiovascular events after CAR-T cell therapy in multiple myeloma: A propensity-matched real-world analysis2025
  2. 2Risk of second primary malignancy following chimeric antigen receptor T-cell therapy: A real-world cohort study2025 · 1 citations
  3. 3Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study2025
  4. 4Risk of second primary hematological malignancy post chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Propensity-matched analysis using trinetx database2025
  5. 5Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival2025